Ascidian Therapeutics Welcomes New Leadership Amid Strategic Innovations

Ascidian Therapeutics, a pioneering biotechnology firm focused on treating human diseases through RNA rewriting, has officially announced a significant leadership transition. This change is set against the backdrop of the company's ongoing commitment to advance RNA editing technologies.

On July 21, 2026, Michael Ehlers, M.D., Ph.D., stepped down from his dual role as both President and Chief Executive Officer. However, he will continue to contribute to the organization as the Chair of the Board of Directors. In this capacity, Ehlers will guide the scientific and strategic directives of the company, leveraging his vast expertise in the field.

The newly appointed President, Daniel Rosan, who formerly served as Chief Financial Officer and Chief Business Officer, is now tasked with leading the company's strategic initiatives while maintaining his existing responsibilities. Rosan expressed excitement about his new role, emphasizing the importance of execution in advancing Ascidian’s projects and fulfilling the expectations of its partners.

"Ascidian was built around a bold idea that RNA editing could unlock new possibilities for patients with serious genetic diseases," stated Ehlers. He took pride in the company's accomplishments, particularly in developing a first-in-class RNA exon editing platform that promises to pave new pathways for treatment.

Rosan echoed this sentiment, asserting that the company possesses the science, the team, the partnerships, and a robust strategy to fully realize the potential of RNA exon editing. His focus will remain on executing Ascidian's ambitious pipeline which includes innovative therapies for genetic diseases like Stargardt disease.

This leadership reshuffling arrives at a pivotal moment for Ascidian as it progresses its clinical developments, most notably the ACDN-01 program targeted at treating Stargardt disease. This condition, which leads to vision loss, has no approved therapies, making Ascidian’s advancements critical in the field.

Ascidian Therapeutics has gained recognition for its groundbreaking approach that involves precise post-transcriptional gene editing, leading to the creation of fully functional proteins. The company is currently engaged in both wholly-owned and partnered programs across various therapeutic areas including retinal, renal, neurological, neuromuscular, and genetically defined diseases. The targeted delivery of RNA exon editors represents a revolutionary treatment paradigm for patients, potentially allowing them to receive a single dose capable of correcting underlying genetic issues.

The transition in leadership reflects Ascidian's commitment to fostering a progressive culture that emphasizes innovation and responsiveness to the ever-evolving landscape of biotechnology. Looking ahead, both Ehlers and Rosan are poised to drive the company toward realizing its mission to redefine disease treatment through cutting-edge RNA technology.

Ascidian's leadership change stands not only as a reorganization of roles but also as an embodiment of the company's larger goal: to open new therapeutic possibilities for patients and their families seeking breakthrough solutions. As the firm continues to accelerate its initiatives, it remains focused on the relentless pursuit of scientific excellence and transformative medicine.

For more information about Ascidian Therapeutics, visit Ascidian.com. To learn more about the ongoing clinical trials for Stargardt disease, please visit AscidianClinicalTrials.com.